Journal for ImmunoTherapy of Cancer · 2021 · 121 citations · 48 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyColorectal CancerDendritic Cell BiologyImmune Cell InfiltrationTumor Immune MicroenvironmentTumor-infiltrating LymphocytesAdaptive Antitumor ImmunityImmunofluorescence ImagingImmunofluorescence StainingInnate Antitumor ImmunityPrimary Tumor CharacterizationTertiary Lymphoid StructuresTumor Immune Microenvironment ProfilingTumor Progression Microenvironment
Background Plasmacytoid dendritic cells (pDCs) play a key role in the induction and maintenance of antitumor immunity. Conversely, they can act as tolerogenic DCs by inhibiting tumor-directed immune responses. Therefore, pDCs may profoundly influence tumor progression. To gain novel insights into the role of pDCs in colon cancer, we investigated the frequency and clinical relevance of pDCs in primary tumor tissues from patients with colon cancer with different clinicopathological characteristics. Methods Immunohistochemical stainings were performed to explore the frequency of tumor-infiltrating BDCA-2 + pDCs in patients with colon cancer. Statistical analyses were conducted to determine an association between the pDC density and clinicopathological characteristics of the patients. Furthermore, we used multiplex immunofluorescence stainings to evaluate the localization and phenotype of pDCs in stroma and tertiary lymphoid structures (TLS) of colon cancer tissues. Results An increased density of infiltrating pDCs was associated with lower Union for International Cancer Control (UICC) stages. Furthermore, a higher pDC frequency was significantly correlated with increased progression-free and overall survival of patients with colon cancer. Moreover, a lower number of coloncancer-infiltrating pDCs was significantly and independently linked to worse prognosis. In addition, we found that a proportion of pDCs shows a nuclear expression of the transcription factor interferon regulatory factor 7 (IRF7), which is characteristic for an activated phenotype. In various tumor stroma regions, IRF7 + pDCs were located in the neighborhood of granzyme B-expressing CD8 + T cells. Moreover, pDCs were identified as a novel component of the T cell zone of colon cancer-associated TLS, which are major regulators of adaptive antitumor immunity. A proportion of TLS-associated pDCs displayed a nuclear IRF7 expression and was preferentially located close to CD4 + T cells. Conclusions These results indicate that higher densities of tumor-infiltrating pDCs are associated with prolonged survival of patients with colon cancer. Moreover, colon cancer-infiltrating pDCs may represent a novel prognostic factor. The colocalization of activated pDCs and T cells in tumor stroma and within TLS may contribute to the correlation between higher pDC densities and better prognosis. In addition, our findings may have implications for the design of novel immunotherapeutic strategies that are based on targeting colon cancer-infiltrating pDCs.
48
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao et al. · Nature · 2020 · 2.7K citations · Full text
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita, Martin Lauss, Adriana Sanna et al. · Nature · 2020 · 2.3K citations · Full text
Medicine, Immunology, Oncology +12
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Kenya Honda, Hideyuki Yanai, Hideo Negishi et al. · Nature · 2005 · 2.2K citations